A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

NCT05199051 · clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
19
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Centre Antoine Lacassagne

Collaborators